Sage takes another hit as Alzheimer's drug is canned
WEB15 hours ago · Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the plug on the drug in Parkinson's disease. ... News of the outcome of ...
Sage Therapeutics Announces Topline Results from the Phase 2 …
WEB1 day ago · About dalzanemdor (SAGE-718) Dalzanemdor (SAGE-718) is a first-in-class investigational NMDA receptor positive allosteric modulator (PAM). Sage has an ongoing placebo-controlled Phase 2 study ...
Sage Therapeutics scraps Alzheimer’s drug development after trial …
WEB1 day ago · Oct 8 (Reuters) - Sage Therapeutics (SAGE.O) said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late ...
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor …
WEB1 day ago · Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive ...
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2
WEB1 day ago · Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington’s. Sage Therapeutics has seen another clinical trial go up in smoke. The biotech called time on ...
Sage continues downslide as Alzheimer’s study fails
WEB1 day ago · Published Oct. 8, 2024. Jacob Bell Senior Reporter. Sage said on Oct. 8 it would stop developing dalzanemdor for Alzheimer’s based on the results of a Phase 2 trial. noparrit via Getty Images. Alzheimer’s disease remains one of the world’s most indomitable illnesses, and on Tuesday it defeated yet another potential treatment in an ...
Sage Therapeutics Ends Development of Dalzanemdor in …
WEB1 day ago · Sage on Monday said dalzanemdor didn't show a statistically significant difference versus placebo on the primary outcome measure of cognitive ability in a Phase 2 study in patients with mild ...
Sage Therapeutics Announces Topline Results from the
WEB1 day ago · Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
Sage Therapeutics Announces Topline Results from Phase 2 …
WEBApr 17, 2024 · About dalzanemdor (SAGE-718) Dalzanemdor (SAGE-718), a first-in-class investigational NMDA receptor positive allosteric modulator (PAM), is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, including Huntington’s disease (HD) and Alzheimer’s disease (AD).
Sage Therapeutics (SAGE) Announces Topline Results from the …
WEB1 day ago · Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor ...
- Some results have been removed